Pre-Activity Survey Question Title 1. The most common route of opioid abuse is: Injection Smoking Ingestion Snorting Question Title 2. Which of the following opioid formulations does not contain abuse-deterrent technology? Embeda® Hysingla® Duragesic® MorphaBond® Question Title 3. Current abuse-deterrent technologies can prevent all of the following methods of abuse except: Ingestion of supratherapeutic doses of non-manipulated product Crushing of tablets to fine powder for snorting Dissolving the opioid to be drawn into a syringe for injection Extraction of the opioid by water or alcohol Question Title 4. Which of the following is an opioid antagonist? Nortriptyline Disulfiram Naltrexone Bupropion Question Title 5. When is the optimal time to teach patients about the risk of opioid-induced constipation? Prior to initiating opioid treatment At the first follow-up visit after initiating opioid treatment At first signs of constipation Depends on the prescribed opioid Question Title 6. In the gastrointestinal tract, opioids primarily exert their effect on: Beta cells Mu-opioid receptors H2-receptors Gamma-opioid receptors Question Title 7. Currently available PAMORAs include all of the following except: Naloxegol Methylnaltrexone Naldemedine Docusate Question Title 8. The most appropriate treatment option for a patient taking morphine and OTC laxatives who is diagnosed with OIC is: Discontinuing opioid use until OIC is resolved Switching to another OTC laxative Doubling the dose of laxative Initiating treatment with PAMORA Done
